Rubius Therapeutics ramps up R&D costs, reports $49M loss in Q3

PROVIDENCE – Rubius Therapeutics Inc. reported a $49 million loss in the third quarter, or 55 cents per diluted share, a decline from a $40.9 million loss one year prior, or 51 cents per share, the clinical-stage biopharmaceutical company said Monday. The company, which is designing products for the potential treatment of cancer and autoimmune…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

If you have already logged in and are still seeing this message, please refresh the page as your browser is caching the old content.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.